Gary C. Starling

Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies

Abstract Background Chimeric antigen receptor (CAR) T cells targeting B cell maturation antigen (BCMA) have demonstrated considerable therapeutic advantages in treating multiple myeloma (MM) patients, increasing progression-free survival and overall survival compared to standard-...